Retirement Systems of Alabama lifted its position in shares of Inogen Inc (NASDAQ:INGN) by 1.8% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 23,286 shares of the medical technology company’s stock after acquiring an additional 401 shares during the quarter. Retirement Systems of Alabama owned approximately 0.11% of Inogen worth $2,221,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the company. South Dakota Investment Council bought a new position in Inogen in the 4th quarter worth about $87,000. First Mercantile Trust Co. purchased a new position in shares of Inogen during the 4th quarter valued at about $99,000. Advisor Group Inc. raised its holdings in shares of Inogen by 210.0% during the 4th quarter. Advisor Group Inc. now owns 992 shares of the medical technology company’s stock valued at $123,000 after buying an additional 672 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Inogen by 30.2% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,113 shares of the medical technology company’s stock valued at $138,000 after buying an additional 258 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Inogen by 9.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,276 shares of the medical technology company’s stock valued at $158,000 after buying an additional 112 shares in the last quarter. Institutional investors own 98.63% of the company’s stock.
Shares of INGN stock traded down $0.93 during trading hours on Wednesday, reaching $68.06. The company’s stock had a trading volume of 292,199 shares, compared to its average volume of 622,540. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.70 and a current ratio of 7.35. Inogen Inc has a one year low of $64.01 and a one year high of $287.79. The firm has a market cap of $1.51 billion, a P/E ratio of 29.59, a P/E/G ratio of 2.82 and a beta of 1.39.
Inogen (NASDAQ:INGN) last released its quarterly earnings results on Tuesday, May 7th. The medical technology company reported $0.24 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.29 by ($0.05). Inogen had a net margin of 12.56% and a return on equity of 15.59%. The firm had revenue of $90.20 million for the quarter, compared to the consensus estimate of $89.69 million. During the same quarter in the prior year, the firm earned $0.48 earnings per share. The company’s revenue for the quarter was up 14.1% compared to the same quarter last year. As a group, equities analysts predict that Inogen Inc will post 1.63 EPS for the current year.
A number of equities analysts recently weighed in on the company. Stifel Nicolaus decreased their price objective on Inogen from $160.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. JPMorgan Chase & Co. cut Inogen from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $175.00 to $72.00 in a research note on Wednesday, May 8th. Needham & Company LLC decreased their price target on Inogen from $191.00 to $111.00 and set a “strong-buy” rating on the stock in a research note on Wednesday, May 8th. BidaskClub upgraded Inogen from a “strong sell” rating to a “sell” rating in a research report on Tuesday, May 7th. Finally, ValuEngine lowered Inogen from a “hold” rating to a “sell” rating in a research report on Thursday, February 28th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $121.60.
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Featured Story: Why do companies issue convertible shares?
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.